New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For OPTR;CBST;AZN;GSK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 8, 2014
13:12 EDTCBSTMerck paid full price but made good deal for Cubist, says UBS
Subscribe for More Information
12:40 EDTCBSTOn The Fly: Midday Wrap
Subscribe for More Information
12:25 EDTCBSTAntibiotic makers rise after Merck agrees to buy Cubist
Subscribe for More Information
10:11 EDTCBSTHigh option volume stocks
Subscribe for More Information
09:20 EDTCBSTOn The Fly: Pre-market Movers
Subscribe for More Information
08:30 EDTCBSTMerck says deals with Cubist includes $250M break-up fee clause
Subscribe for More Information
08:21 EDTCBSTMerck says looked at all risks, including patent litgation, before Cubist deal
Subscribe for More Information
08:11 EDTCBSTCubist volatility elevated into Merck acquiring for $8.4B in cash
Subscribe for More Information
08:08 EDTCBSTMerck says about $9.5B of debt to be issued related to Cubist deal
Subscribe for More Information
07:13 EDTCBSTMerck to host conference call
Subscribe for More Information
07:05 EDTAZNInnocoll appoints Tony Zook as CEO
Innocoll AG (INNL) announced that Tony Zook, formerly executive vice president, Global Commercial Operations, at AstraZeneca (AZN), has been appointed CEO effectively immediately. Michael Myers, will continue with the company as head of Portfolio Operations.
07:01 EDTCBSTMerck to acquire Cubist for $102 per share in cash, or $9.5B
Subscribe for More Information
07:00 EDTCBSTMerck to acquire Cubist for $102 per share in cash
Subscribe for More Information
December 7, 2014
16:29 EDTCBSTMerck in discussions to buy Cubist for $7B, Bloomberg reports
Subscribe for More Information
December 5, 2014
09:49 EDTAZNUBS European pharmaceuticals analysts holds analyst/industry conference call
Subscribe for More Information
06:04 EDTGSKGSK won't pursue divestment of certain brands in established products portfolio
As announced at the company’s Q2 results in July, GSK started a process to consider the divestment of certain North American and European brands in its Established Products Portfolio.The company has evaluated all bids received and has concluded, consistent with its key criteria of maximizing shareholder value, not to pursue divestment of these products.
December 4, 2014
08:45 EDTAZNAbbVie price target raised to $80 from $72 at Jefferies
Jefferies raised its price target for AbbVie shares to $80 while calling the company one of its top five global pharma picks for 2015. The firm's top U.S. pick is Pfizer (PFE) and its top Europe pick is Novartis (NVS). Bayer (BAYRY) and AstraZeneca (AZN) round out the top five. Jefferies thinks AbbVie's "strong momentum" will continue into the first half of 2015 and keeps a Buy rating on the name.
December 3, 2014
19:11 EDTAZNAstraZeneca, Shire interested in Ariad, Daily Mail reports
Ariad (ARIA) is trading higher on speculation that both AstraZeneca (AZN) and Shire (SHPG) are interested in the company with the possibility of an ensuing auction, according to the Daily Mail, which added that analysts see an acquisition price for Ariad of more than $20 per share. Reference Link
17:33 EDTGSKGSK to shed U.S. jobs as Advair sales slow, Reuters says
GlaxoSmithKline confirmed U.S. job reductions saying "several hundred" commercial and research positions will be eliminated as the company consolidates its operations after the company's Advair sales slowed, says Reuters. Reference Link
16:05 EDTGSKArray BioPharma to regain worldwide rights to Binimetinib
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use